Viopas Venture Consulting GmbH
Viopas Venture Consulting was founded by a team of industry professionals combining the expertise of serial entrepreneurs, venture capital fund managers and senior C-level Bio-Pharma executives.
All team members contribute their substantial industry track record of managing and investing in life science companies, developing pharmaceutical products, assessing medical devices, diagnostics, services and research tools, and providing financial expertise. The team has extensive expertise in development of pharmaceutical products for a wide range of diseases, such as immunology/oncology, ophthalmology, neurology, neuromuscular conditions and rare diseases.
As entrepreneurs we share our knowledge with the next generation of inspiring and talented innovators to produce innovative healthcare solutions for the benefit of patients.
About Viopas Venture Consulting GmbH:
| Ownership Structure | Viopas Venture Consulting is run by its Managing Partners on two Swiss offices and a 100 % subsidiary in Germany |
| Managing Partners | Switzerland
Simon Nebel, PhD, MBA, (Founder), longstanding track record as a venture capital investor, invested in and managed more than 20 life science companies, Chairman of the BoD of Marinomed AG Thomas Meier, PhD, dynamic life-science entrepreneur and internationally recognized neuroscientist with excellent track record in clinical research of orphan diseases. Executive CEO and CSO positions, Partner at Board Advisors Deutschland AG Ulf Grawunder, PhD, serial entrepreneur with strong track record in company building and exits (ex-CEO and founder of NBE Therapeutics AG). Co-founder/CEO of T-CURX GmbH, Vice President of Swiss Biotech Association Daniel Pajer, PwC Switzerland, Partner Asset and Wealth Management with particular focus on risk management and compliance, Member Board of Directors of Raiffeisenbank Basel Germany Thomas Loeser, 20+ year track record as CFO of several German, Swiss and US biotech companies with particular focus on transatlantic growth/financing strategies and US capital markets. Member of Harvard Alumni Association |
| Areas of Business/Services | Comprehensive development expertise in oncology/immunology, ophthalmology, rare diseases, neurology and neuromuscular diseases
Complimentary team expertise in CMC/drug development, corporate finance/governance. Strategic counsel to investors interested in the healthcare sector, including family offices, high-net worth individuals, and institutional investors. |
Contact:
| Addresses | Thiersteinerallee 17, CH-4057 Basel Poststrasse 20, CH-8610 Uster Am Klopferspitz 19, D-82152 Martinsried |
| Telephone | +49 173 565 26 97 |
| info@viopasventure.de | |
| Web Address | www.viopasventure.ch |
| Social Media | |
| Date of Incorporation/Number of Employees | 2016/7 |
| Other | Company references: Marinomed AG, DyCare, Santhera AG |
- Cicor: Übernahme der STS Defence Limited abgeschlossen
- Kleine Moleküle mit großer Wirkung
- Zell- und Gentherapien in Leipzig: Stärker durch Vernetzung
- Lumatix Biotech gewinnt BioRiver Boost! 2022
- Medizinische Innovationen, die die Welt verändern
- Willkommen, grüne Medizin!
- IPO im Fokus: hohes Potential im Arzneimittel-Parallelmarkt der EU für Abacus Medicine
- Merck eröffnet erstes M Lab Collaboration Center in Europa
- Neuengagement bei Entwickler von elektronischer Nase
- Digitalisierung ist Chefsache geworden
- Cannabis als Medizin
- 1. FORUM Science & Health 2017 mit großer Resonanz